Characteristics and long‐term outcomes of advanced pleural mesothelioma in Latin America (MeSO‐CLICaP)

Miniatura

Archivos

Rojas L., Cardona A.F., Trejo-Rosales R., Zatarain-Barrón Z.L_2019.pdf (458.05 KB)

Fecha

2019

Autores

Título de la revista

Publicado en

Thoracic cancer, 1759-7714, Vol. 10, Nro. 3, 2019, 508-518

Publicado por

Blackwell Publishing Asia Pty

URI

https://hdl.handle.net/20.500.12495/1840

URL de la fuente

https://onlinelibrary.wiley.com/doi/10.1111/1759-7714.12967

ISSN de la revista

Título del volumen

Resumen

Descripción

Abstract

Background Malignant pleural mesothelioma (MPM) is an aggressive tumor, associated with poor prognosis. There is a lack of information about the clinical and pathological features related with survival in the Latin American population. Methods The MeSO‐CLICaP registry identified 302 patients with advanced MPM diagnosed and treated between January 2008 and March 2016. The Cox model was applied to determine the variables associated with survival. A random forest tree model was built to predict the response to first‐line chemotherapy among Latin American patients. Results The median age was 61.1 years (SD 10.6 years), 191 (63.2%) were men, 65.9% were ever smokers, and 38.7% had previous exposure to asbestos. A total of 237 (78.5%) had epithelioid tumors, and 188 (62.3%) and 114 (37.7%) cases had stage III or IV MPM, respectively. A total of 49 patients (16.2%) underwent pleurectomy, 57 (18.9%) received radiotherapy, and 279 patients received first‐line platinum‐based chemotherapy. The overall response rate to first‐line chemotherapy was 40.4%, progression‐free survival to first‐line treatment was 5.7 months (95% CI 4.9–6.5), and 63 (20.8%) patients had pemetrexed maintenance. The median overall survival was 16.8 months (95% CI 13.0–20.5), and multivariate analysis found that stage (P = 0.013), and pleurodesis (P = 0.048), were independent prognostic factors for first‐line overall survival. The model to predict response to first‐line chemotherapy obtained a 0.98 area under the curve, a sensitivity of 93%, and a specificity of 95% for detecting responders and non‐responders. Conclusion This study identifies factors associated with clinical benefit from chemotherapy among advanced MPM Latin American patients, emphasizing the impact of histology and the clinical benefit of chemotherapy on outcomes.

Palabras clave

Keywords

Asbestos exposure, Chemotherapy, Latin America

Temáticas

Mesotelioma
Radioterapia
Neoplasias malignas

Citación

Colecciones

Artículos